United States Paraganglioma Treatment Market Set to Surge: Innovative Therapies Drive Global Growth 2025 | Top 3 key players - Merck & Co., AstraZeneca, Progenics Pharmaceuticals, Inc.

Market Overview:

The Global Paraganglioma Treatment Market is expected to grow at a CAGR of 6.42% during the forecast period (2024-2031). The Market is growing due to rising prevalence of paraganglioma, increased awareness for early diagnosis, and advancements in targeted therapies and minimally invasive treatments.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://datamintelligence.com/download-sample/paraganglioma-treatment-market?sz

The Paraganglioma Treatment Market encompasses therapies and interventions for managing paragangliomas, rare neuroendocrine tumors arising from paraganglia cells. It includes surgical procedures, radiotherapy, targeted therapies, and emerging pharmacological treatments aimed at tumor removal, growth inhibition, or symptom management. The market is driven by advancements in precision medicine, early diagnosis, and increasing awareness of rare tumor management globally.

Industry Recent Developments:

United States:

✅ In May 2025, the U.S. FDA approved belzutifan (Welireg, Merck & Co., Inc.) for treatment of adult and pediatric patients 12 years and older with pheochromocytoma or paraganglioma, providing a new targeted therapy option. (May 2025)

✅ In October 2025, the U.S. FDA accepted for priority review a supplemental new drug application for expanding the approval of Welireg (belzutifan) for advanced pheochromocytoma and paraganglioma treatment, signaling further regulatory progress. (October 2025)

✅ The U.S. market continues to see innovations in gene therapy and personalized medicine approaches tailored to genetic profiles of paragangliomas, driving growth with more effective and minimally invasive treatments available in 2025.

Japan:

✅ Japan Endocrine Society issued updated Clinical Practice Guidelines for the diagnosis and management of pheochromocytoma and paraganglioma, emphasizing improved diagnostic protocols and treatment strategies in October 2025. (October 2025)

✅ Increased adoption of advanced diagnostic tools such as next-generation sequencing (NGS) and AI in radiology to enhance early detection and personalized treatment pathways for paraganglioma patients in Japan during 2025.

✅ Ongoing research and development in Japan focus on expanding the use of peptide receptor radionuclide therapy (PRRT) and targeted radionuclide treatments to improve outcomes for paraganglioma cases in 2025.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/paraganglioma-treatment-market?sz

Major 5 Key Players:

1. Merck & Co.
Merck has made a significant impact in the treatment of paraganglioma with its drug Welireg (belzutifan). In May 2025, the U.S. Food and Drug Administration (FDA) expanded the use of Welireg to include the treatment of metastatic or inoperable pheochromocytoma and paraganglioma (PPGL) in patients aged 12 and older. This approval marked Welireg as the first oral treatment for these rare adrenal gland tumors, offering a new therapeutic option for patients

2. AstraZeneca
AstraZeneca is actively involved in the oncology space, with a focus on developing targeted therapies for various cancers. While specific products for paraganglioma are not detailed, the company's extensive oncology pipeline and commitment to cancer research position it as a key player in the broader neuroendocrine tumor treatment landscape.

3. Progenics Pharmaceuticals, Inc.
Progenics Pharmaceuticals, now part of Lantheus Holdings, has been a significant contributor to the neuroendocrine tumor treatment market. Their radiopharmaceuticals, such as Pluvicto (lutetium Lu 177 vipivotide tetraxetan), have shown efficacy in treating neuroendocrine tumors. While specific applications to paraganglioma are not explicitly mentioned, the company's expertise in radiopharmaceuticals supports its role in the treatment of related conditions.

4. Advanced Accelerator Applications (AAA)
A subsidiary of Novartis, Advanced Accelerator Applications specializes in the development of radioligand therapies for cancer treatment. Their product Lutathera (lutetium Lu 177 dotatate) is approved for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. Given the biological similarities between these tumors and paragangliomas, Lutathera may offer therapeutic benefits for paraganglioma patients, highlighting AAA's role in the treatment landscape.

5. Pfizer Inc.
Pfizer is a leading global biopharmaceutical company with a diverse oncology portfolio. While specific products targeting paraganglioma are not detailed, Pfizer's ongoing research and development efforts in oncology contribute to the broader understanding and treatment options for neuroendocrine tumors, including paragangliomas

FDA Approval: Belzutifan (Welireg) for Paraganglioma:

On May 14, 2025, the U.S. Food and Drug Administration (FDA) approved belzutifan (Welireg), developed by Merck & Co., Inc., for the treatment of adult and pediatric patients aged 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL). This approval marked the first FDA-sanctioned oral therapy for PPGL, offering a significant advancement in treatment options for this rare neuroendocrine tumor.

Mergers & Acquisitions:

In a strategic move to bolster its oncology portfolio, Merck & Co., Inc. acquired U.S.-based biotech firm SpringWorks Therapeutics for $3.9 billion in an all-cash deal. SpringWorks specializes in treatments for rare tumors, including desmoid tumors and neurofibromatosis type 1, thereby enhancing Merck's presence in the rare disease and cancer treatment markets.

Looking For Full Report? Get it Here: https://www.datamintelligence.com/buy-now-page?report=paraganglioma-treatment-market

Segments Covered in the Paraganglioma Treatment Market:

1. By Tumor Site of Origin
Paragangliomas can develop in different anatomical locations, influencing treatment approaches:

Head & Neck Paragangliomas: These are the most common, accounting for approximately 65-70% of cases. They often present as carotid body tumors, jugular paragangliomas, and vagal paragangliomas. The head and neck segment held a significant market share in 2023.

Abdominal Paragangliomas: Typically located near the adrenal glands, these tumors can be functional (secreting catecholamines) or non-functional.

Pelvic Paragangliomas: Less common, these tumors are often asymptomatic and may be discovered incidentally.

2. By Disease Type
Paragangliomas are categorized based on their functionality and genetic associations:

Functional Paragangliomas: These tumors secrete catecholamines, leading to symptoms like hypertension and palpitations. They are often associated with genetic mutations such as SDHB and SDHD.

Non-Functional Paragangliomas: Typically asymptomatic, these tumors do not secrete hormones and are often discovered incidentally.

Metastatic Paragangliomas: These are rare and occur when the tumor spreads to other parts of the body, complicating treatment options.

3. By Treatment Modality
Treatment strategies vary based on tumor characteristics and patient health:

Surgical Resection: The primary treatment for localized tumors, especially in the head and neck region.

Radiation Therapy: Used for inoperable tumors or as adjuvant therapy post-surgery.

Chemotherapy: Generally reserved for metastatic or recurrent cases.

Targeted Therapy: Emerging as a significant treatment option. For instance, the FDA approved belzutifan (Welireg), a HIF-2α inhibitor, as the first oral treatment for metastatic or inoperable pheochromocytoma and paraganglioma in 2025.

4. By End-User
Treatment settings influence patient access and care delivery:

Hospitals: Serve as primary centers for diagnosis and surgical treatment.

Specialty Clinics: Provide focused care, often for specific tumor types or advanced therapies.

Cancer Research Centers: Engage in clinical trials and advanced treatment modalities.

Others: Includes outpatient facilities and telemedicine platforms.

5. By Distribution Channel
The availability of treatments through various channels affects patient access:

Hospital Pharmacies: Offer immediate access to prescribed medications.

Drug Stores & Retail Pharmacies: Provide outpatient access to medications.

Online Pharmacies: Increasingly popular for convenience, especially for maintenance therapies

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

People Also Ask:

◆ How big is the Paraganglioma Treatment Market in 2025?
◆ What is the projected growth rate of the Paraganglioma Treatment Market through 2033?
◆ Who are the key players in the Paraganglioma Treatment Market?
◆ Which region is expected to dominate the industry during the forecast period?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.